Torrent Pharma
Growth unavailable
Q2 FY2027 · Period ended 30 Sep 2026
Basis: Consolidated, as printed in the company's Q2 FY27 results press release dated 23 Oct 2026
Reported revenue (₹ crore, as printed (rounded to whole crore)): 4,979
Read summary and comparison caveats
Torrent Pharma's Q2 FY27 consolidated revenue was ₹4,979 crore against ₹3,302 crore a year earlier (printed +50.8%), while PAT was ₹534 crore against ₹591 crore (printed -9.6%). Operating EBITDA before exceptional items was ₹1,666 crore at a printed margin of 33.5%.
- Figures are from the company's own Q2 FY27 results press release (4-page PDF, Ahmedabad, 23 Oct 2026, hosted on torrentpharma.com), read in full on 15 Nov 2026. It is a press release summary, not the filed results statement, so only the lines it prints are shown, rounded as printed. It prints year-on-year comparisons and no quarter-on-quarter columns, so none are shown or derived.
- Comparability, from the release: it refers to the merger, effective 8 July 2026, with its JB business. JB business revenue is printed as ₹1,086 crore of the ₹4,979 crore total, and base business revenue as ₹3,893 crore (printed +18%). The release prints the JB split only for Q2 FY27, so the printed total growth of 51% is not a like-for-like base comparison; the +18% is the release's base business figure.
- Base business as printed: India ₹2,181 crore (+20%), Brazil ₹440 crore (+38%), United States ₹417 crore (+24%), Germany ₹283 crore (-7%). The release says integration of JB led to a transient impact on revenues in Q2 FY27 and attributes Germany's decline to a third-party supplier disruption and loss of certain high volume tenders.
- H1 FY27 as printed: revenues ₹9,900 crore (₹6,480 crore in H1 FY26), operating EBITDA ₹3,330 crore, PAT ₹1,100 crore (₹1,139 crore), exceptional item ₹(31) crore.
- Company statements, attributed: market-share and growth comparisons in the release (for example India growth against IPM growth of 12%, Gx Semaglutide share of 32%) are the company's own, citing PharmaTrac and IQVIA, and are not verified here.
Checked 15 Nov 2026
Open original filing